Key Points Genetics probably plays a part in GLP-1 response, but it is not the main practical explanation in most cases A new Nature paper found GLP1R and GIPR variants associated with efficacy and side effects, but effect sizes are modest Non-genetic factors drug choice, dose, duration, sex, diabetes status still explain more variation than genetics Current evidence does not justify routine genetic testing before prescribing semaglutide or tirzepatide Most apparent non-responders have correctable clinical reasons for poor response If you are wondering why GLP-1 drugs work better for some people , the short answer is this: genetics probably plays a part, but it is not the main practical explanation in most cases
It is not yet FDA-approved (still in Phase 3 trials as of February 2026), so it is only available through research suppliers
Baltacolu E, Yuva P, Aydn G, Alver A, Kahraman C, Karabulut E, Akaln FA
DM Dylan M
Use of respiratory syncytial virus vaccines in adults aged 60 years: updated recommendations of the advisory committee on immunization practices - United States